Skip to main content

Table 5 Stratified analysis of possible confounding factors affecting response to icatibant

From: Review of icatibant use in the Winnipeg Regional Health Authority

Category

Stratification

Time to OSR, median, hours

p-value (*< 0.05), pairwise

Time to FCO, median, hours

p-value (*< 0.05), pairwise

History or diagnosis

HAE

ACEI-induced

1.13

4.86

0.05

3.50

19.53

0.02*

Atopy

None

8.35

7.94

0.40

19.53

7.94

0.40

Smoking

None

1.00

3.20

0.60

9.75

7.38

0.70

Body system

Face/oropharolarynx involvement

None

2.17

1.00

0.50

8.93

2.50

0.10

Abdominal involvement

None

1.25

2.17

0.71

2.92

14.64

0.05

Cutaneous involvement

None

1.00

1.43

0.30

18.83

7.75

0.40

Initial treatment

Antihistamine

None

3.13

1.13

0.40

14.63

4.08

0.08

Epinephrine

None

4.08

1.34

0.90

19.53

5.53

0.10

Glucocorticoids

None

4.08

1.00

0.20

19.53

3.50

0.03*

C1-INH

None

3.20

1.13

0.70

6.47

7.75

0.90

FFP

None

4.53

1.14

0.40

9.75

5.83

0.30

  1. FCO final clinical outcome, OSR onset of symptom relief